Free Trial

Laboratory Co. of America (LH) Stock Forecast & Price Target

Laboratory Co. of America logo
$248.62 +1.87 (+0.76%)
Closing price 05/30/2025 03:59 PM Eastern
Extended Trading
$248.25 -0.37 (-0.15%)
As of 05/30/2025 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Laboratory Co. of America - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
11

Based on 14 Wall Street analysts who have issued ratings for Laboratory Co. of America in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 3 have given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for LH.

Consensus Price Target

$272.92
9.77% Upside
According to the 14 analysts' twelve-month price targets for Laboratory Co. of America, the average price target is $272.92. The highest price target for LH is $300.00, while the lowest price target for LH is $230.00. The average price target represents a forecasted upside of 9.77% from the current price of $248.62.
Get the Latest News and Ratings for LH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Laboratory Co. of America and its competitors.

Sign Up

LH Analyst Ratings Over Time

TypeCurrent Forecast
5/31/24 to 5/31/25
1 Month Ago
5/1/24 to 5/1/25
3 Months Ago
3/2/24 to 3/2/25
1 Year Ago
6/1/23 to 5/31/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
11 Buy rating(s)
10 Buy rating(s)
11 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$272.92$267.85$265.75$241.86
Forecasted Upside9.77% Upside11.02% Upside5.69% Upside23.98% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

LH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Laboratory Co. of America Stock vs. The Competition

TypeLaboratory Co. of AmericaMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.81
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside9.77% Upside5,969.03% Upside15.20% Upside
News Sentiment Rating
Positive News

See Recent LH News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/12/2025Truist Financial
3 of 5 stars
David Macdonald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$274.00 ➝ $290.00+16.27%
5/6/2025Piper Sandler
2 of 5 stars
David Westenberg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$260.00 ➝ $280.00+13.84%
4/30/2025Barclays
3 of 5 stars
L. Sergott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$240.00 ➝ $250.00+3.79%
4/30/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Eric Coldwell
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$253.00 ➝ $267.00+12.82%
4/2/2025Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jamie Clark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$276.00+18.64%
3/4/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ralph Giacobbe
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$250.00 ➝ $300.00+18.11%
2/6/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tycho Peterson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$275.00 ➝ $290.00+17.25%
1/28/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kevin Caliendo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$293.00 ➝ $286.00+14.61%
1/7/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeIn-Line ➝ Outperform$260.00 ➝ $265.00+15.42%
12/17/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$260.00 ➝ $270.00+17.38%
12/13/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$262.00 ➝ $271.00+16.67%
10/30/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Herholdt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
10/30/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
8/2/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$220.00 ➝ $230.00-2.35%
5/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$261.00 ➝ $243.00+25.49%
3/25/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$250.00+17.23%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$260.00+18.63%
10/31/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$257.00 ➝ $230.00+16.07%
8/14/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$290.00 ➝ $270.00+23.85%
8/2/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$247.41 ➝ $231.00+8.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 02:31 AM ET.


Should I Buy Laboratory Co. of America Stock? LH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, May 28, 2025. Please send any questions or comments about these Laboratory Co. of America pros and cons to contact@marketbeat.com.

Laboratory Co. of America
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Laboratory Co. of America Holdings:

  • The stock has received multiple upgrades from analysts, with price targets raised to as high as $290, indicating strong confidence in its future performance.
  • Laboratory Co. of America Holdings reported earnings per share that exceeded analysts' expectations, showcasing its ability to generate profit effectively.
  • The current stock price is around $242, which is near its 52-week high, suggesting positive market sentiment and potential for further growth.
  • Institutional investors hold a significant majority of the company's stock, which often indicates stability and confidence in the company's long-term prospects.
  • The company has shown a year-over-year revenue increase, reflecting its growth potential in the medical research sector.

Laboratory Co. of America
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Laboratory Co. of America Holdings for these reasons:

  • Insider selling has occurred, with executives reducing their ownership stakes, which can sometimes signal a lack of confidence in the company's future performance.
  • The stock has a relatively high P/E ratio, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • The company has a debt-to-equity ratio of 0.67, which, while manageable, suggests that it is not entirely free from debt obligations that could impact financial flexibility.
  • Recent trading volumes have been lower than average, which may indicate reduced investor interest or liquidity issues.
  • Market volatility could impact the stock's performance, especially in the context of broader economic conditions affecting the healthcare sector.

LH Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Laboratory Co. of America is $272.92, with a high forecast of $300.00 and a low forecast of $230.00.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last year. There are currently 3 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LH shares.

According to analysts, Laboratory Co. of America's stock has a predicted upside of 9.77% based on their 12-month stock forecasts.

Over the previous 90 days, Laboratory Co. of America's stock had 1 upgrade by analysts.

Laboratory Co. of America has been rated by research analysts at Barclays, Citigroup, Piper Sandler, Redburn Atlantic, Robert W. Baird, and Truist Financial in the past 90 days.

Analysts like Laboratory Co. of America more than other "medical" companies. The consensus rating score for Laboratory Co. of America is 2.86 while the average consensus rating score for "medical" companies is 2.81. Learn more on how LH compares to other companies.


This page (NYSE:LH) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners